Librela for Dogs: The Monthly Arthritis Injection Explained

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-19

Librela is a prescription injectable medication for dogs with osteoarthritis pain. Its active ingredient is bedinvetmab, a fully canine monoclonal antibody that binds and neutralizes nerve growth factor (NGF), a signaling protein that drives pain in arthritic joints. A veterinarian gives it as a subcutaneous injection once a month. The FDA approved Librela for use in dogs in the United States in 2023, and it has been available in some other markets since 2021 [1]. It is not a cure for arthritis and it does not regrow cartilage. It is a pain-control tool, and for many dogs it reduces the lameness, stiffness, and reluctance to move that define chronic joint pain.

This article explains what Librela is, how it differs from the daily pills most owners already know, what the clinical trials actually showed, how quickly owners tend to notice a change, who is a reasonable candidate, and the safety conversation that has unfolded since approval, including the FDA's Dear Veterinarian letter of December 2024 and the resulting label update [2].

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

What Librela Is and What It Is Not

Librela is a biologic drug, not a chemical one. It is a monoclonal antibody, which means it is a lab-produced protein designed to lock onto one specific target. In this case the target is nerve growth factor [7][8]. When bedinvetmab binds NGF, it prevents NGF from docking with its receptors, tropomyosin receptor kinase A (TrkA) and p75 neurotrophin receptor (p75NTR), on sensory nerves [7]. The result is less pain signaling from the joint to the brain.

That mechanism matters for understanding both the benefits and the limits. NGF is not the cause of arthritis. It is one of several amplifiers of pain in an already damaged joint. Blocking it reduces the volume of the pain signal. It does not stop the underlying degenerative process, and it does not address inflammation the way a nonsteroidal anti-inflammatory drug (NSAID) does.

Librela is labeled for alleviation of pain associated with osteoarthritis in dogs [9]. It is not approved to treat soft tissue injuries, post-surgical pain, or acute pain from trauma. It is also not a substitute for weight management, controlled exercise, or physical rehabilitation. Research on anti-NGF antibodies continues to explore other pain conditions, including some cancer-related pain and inflammatory conditions, but those uses remain investigational and are not part of the current label [10].

How Bedinvetmab Works

The NGF pathway

Nerve growth factor was first identified for its role in the development and survival of sensory and sympathetic neurons. In adult animals, NGF takes on a different job. It becomes a key mediator of nociception, the process by which the nervous system detects and transmits painful stimuli [7][8]. In an arthritic joint, inflamed tissue releases NGF. NGF binds to TrkA receptors on pain-sensing nerve endings and sensitizes them. Nerves that were quiet start firing in response to normal movement. This is part of why an arthritic dog limps on a joint that has not changed much on an X-ray in the past month.

NGF also contributes to central sensitization, a state in which the spinal cord and brain become more responsive to pain signals [8]. Chronic pain is not simply a peripheral event. It involves changes in how the nervous system processes input. Blocking NGF at the source can reduce both the peripheral signal and the downstream amplification.

Why a monoclonal antibody rather than a small molecule

Bedinvetmab is a fully caninized antibody. Early anti-NGF antibodies were developed in other species and would have triggered an immune response in dogs if given repeatedly [11]. Caninization is the process of engineering the antibody so its protein backbone matches canine immunoglobulin sequences. This reduces the chance the dog's immune system will recognize the drug as foreign and clear it or react to it [11].

The antibody has a long half-life, which is why monthly dosing works. In the pivotal US field study, the half-life of bedinvetmab was calculated as part of the trial design [3]. A long half-life means the drug stays in circulation long enough to keep NGF neutralized between injections.

What the injection does not do

Bedinvetmab does not reduce joint inflammation directly. It does not slow cartilage loss. It does not reverse bone changes. A dog on Librela can still have progressive osteoarthritis, and the drug can mask some of the pain that would otherwise signal worsening joint disease. This is one of the central safety concerns discussed later in this article [12].

The Clinical Trial Evidence

Two large randomized, double-blind, placebo-controlled field studies form the core of the efficacy data for Librela in dogs. Both used the Canine Brief Pain Inventory (CBPI), a validated owner-completed questionnaire that generates a pain severity score (PSS) and a pain interference score (PIS), each on a 0 to 10 scale.

The European field study

The first pivotal study enrolled 287 client-owned dogs with osteoarthritis. Dogs were randomized to either placebo (saline) or bedinvetmab at 0.5 to 1.0 mg/kg subcutaneously once monthly [4]. Treatment success was defined as at least a 1-point reduction in PSS and at least a 2-point reduction in PIS.

On day 28, 43.5 percent of dogs in the bedinvetmab group achieved treatment success compared with 16.9 percent in the placebo group [4]. The difference was statistically significant. Treatment success continued through day 56 (50.8 percent) and day 84 (48.2 percent) in the bedinvetmab group, while placebo success rates stayed below 25 percent at all time points [4]. After three months, dogs that responded positively entered an open-label continuation phase and received up to six additional doses [4].

The US field study

The US registration study enrolled 272 dogs and used the same design and primary endpoint [3]. On day 28, treatment success rates were 47.4 percent for bedinvetmab and 36.6 percent for placebo [3]. The number needed to treat (NNT) at day 28 was 9.3, meaning about nine dogs needed to be treated for one additional dog to benefit beyond what placebo would have produced. By day 84, the NNT had improved to 4.3, and the standardized effect sizes for both pain scores had increased [3]. This pattern, a modest early response that strengthens with repeated dosing, is consistent with the drug's mechanism and its long half-life. It takes time for the antibody to accumulate and for NGF levels in the joint to be consistently suppressed.

What the numbers mean for an individual dog

A treatment success rate of roughly 45 to 50 percent means that about half of treated dogs met the predefined threshold for meaningful improvement. The other half either did not improve enough to meet that threshold or did not improve at all. This is not a drug that works for every dog. It is also not a drug that fails for every dog. The CBPI thresholds are moderately stringent, and some dogs that do not meet the formal definition of success still show improvement that owners notice.

Quality of life data

A real-world observational study measured health-related quality of life in dogs receiving bedinvetmab using a validated instrument with four domains: energetic and enthusiastic, happy and content, active and comfortable, and calm and relaxed [5]. By day 14, there was a statistically significant improvement in physical wellbeing, emotional wellbeing, and all domains except calm and relaxed. Improvement continued through subsequent assessments [5]. This matters because owners often judge arthritis treatment by whether the dog seems happier and more willing to engage, not just by gait scores.

Comparison with meloxicam

A randomized trial compared bedinvetmab directly with meloxicam, a commonly used NSAID, in 101 dogs with appendicular osteoarthritis [13]. Both groups showed significant improvement from baseline. The bedinvetmab group had a larger mean reduction in Canine Orthopaedic Index scores, but the difference between groups was not statistically significant [13]. In other words, the two treatments performed similarly on the primary efficacy measure in this study. The study hypothesis that bedinvetmab would show superior efficacy and safety was only partially supported [13].

Additional evidence

A randomized trial in obese dogs with osteoarthritis found that bedinvetmab improved objective accelerometer-measured daily activity, CBPI pain scores, and quality of life compared with placebo over 56 days [14]. A separate study in dogs with hip osteoarthritis found that bedinvetmab alone produced significant clinical improvement, and that combining it with photobiomodulation and pulsed electromagnetic field therapy produced faster and greater pain threshold improvements [15]. These are smaller studies, but they add to the picture of a drug that works across different patient populations and can be combined with other modalities.

How Soon Owners See a Change

The clinical trials provide the most reliable timeline. In the European field study, the percentage of dogs achieving treatment success was significantly greater in the bedinvetmab group than in the placebo group from day 7 onward [4]. In the quality of life study, statistically significant improvement in physical and emotional wellbeing was present by day 14 [5].

In practical terms, some owners notice a difference within the first week or two after the first injection. Others notice nothing until after the second dose. The US trial data showed that CBPI treatment success increased after the second dose in both groups, and that the bedinvetmab group plateaued at day 42 while the placebo group began to decline by day 84 [3]. This suggests that the full effect of the drug may not be apparent until the second or third monthly injection.

A reasonable approach is to give the first two or three doses before making a judgment about whether Librela is working. If there is no change at all after three doses, the veterinarian may consider whether the dog's pain is primarily NGF-driven or whether another approach is needed.

Who Is a Candidate for Librela

Librela is approved for dogs with osteoarthritis pain [9]. The typical candidate is a middle-aged to older dog with confirmed or suspected osteoarthritis, often in the hips, knees, elbows, or spine. Many candidates have already tried an NSAID and either did not tolerate it, did not get enough relief from it, or cannot take it because of kidney, liver, or gastrointestinal disease.

Dogs that may be good candidates include:

• Dogs that cannot take NSAIDs because of underlying kidney or liver disease, or a history of gastrointestinal ulcers
• Dogs that have not responded adequately to NSAIDs alone
• Dogs whose owners have difficulty giving daily oral medication
• Dogs that need additional pain control alongside an NSAID or other therapy, under veterinary supervision

Dogs that may not be candidates include:

• Dogs younger than 12 months (the label specifies a minimum age)
• Dogs with active neurologic disease, because the safety discussion below includes neurologic adverse events
• Dogs with a known hypersensitivity to bedinvetmab or any component of the injection
• Pregnant, breeding, or lactating dogs, because safety in these groups has not been established
• Dogs with uncontrolled concurrent disease that the veterinarian judges would make the injection unsafe

The decision is not binary. A dog can be a candidate for Librela and still not be a candidate for discontinuing other treatments. Many veterinarians use Librela as part of a multimodal plan that includes weight management, controlled exercise, joint supplements, physical therapy, and sometimes other analgesics.

How Librela Is Given

Librela is given as a subcutaneous injection, which means under the skin, typically between the shoulder blades or over the back. A veterinarian or trained veterinary technician administers it. The dose is 0.5 to 1.0 mg/kg once monthly [3][4]. The injection is not dispensed for owners to give at home.

The monthly interval is important. The drug's half-life supports a roughly 30-day dosing cycle, and the clinical trials used monthly administration [3][4]. Giving doses late or skipping months may reduce the steady-state effect.

Librela can be given alongside other medications, including NSAIDs. A laboratory safety study specifically evaluated short-term concurrent administration of bedinvetmab with carprofen, an NSAID, and found no treatment-related adverse changes [7]. This does not mean every combination is safe for every dog. It means the specific combination studied did not produce safety signals in laboratory beagles. A veterinarian should review all medications and supplements a dog is taking before starting Librela.

Side Effects and Safety

What the trials showed

In the controlled clinical trials, bedinvetmab was generally well tolerated. The European field study reported that adverse events were similar between the bedinvetmab and placebo groups during the blinded phase [4]. The US field study likewise did not identify a pattern of serious adverse events attributable to the drug during the trial period [3]. Laboratory safety studies in beagles found no treatment-related adverse changes across a range of assessments, including electrocardiography, neurologic and ophthalmic evaluations, and radiographic monitoring of joints [7].

Post-approval safety data

Once a drug is used in a much larger and more diverse population than any trial can enroll, new safety signals can emerge. A global pharmacovigilance review covering the period from first market introduction in February 2021 through June 2024 analyzed adverse event reports from the manufacturer's database [1]. During that period, 18,102,535 doses of bedinvetmab were sold, and 17,162 adverse events were reported in dogs, a rate of 9.48 events per 10,000 treated animals (doses) [1]. Eight clinical signs were classified as rare (1 to 10 events per 10,000 treated animals), with lack of efficacy having the highest rate at 1.70, followed by polydipsia (increased thirst), ataxia (wobbliness), polyuria/pollakiuria (increased urination), anorexia, lethargy, and death [1].

That reporting rate is low in absolute terms. But pharmacovigilance data have limitations. Reporting is voluntary, and the rate reflects what was reported, not necessarily what occurred. The authors of that review noted that reporting patterns can be influenced by how long a product has been on the market, the region, and local veterinary practices [1].

The FDA Dear Veterinarian letter and label update

In December 2024, the FDA issued a Dear Veterinarian letter notifying veterinarians about adverse events reported in dogs treated with Librela [2]. The letter described reports of neurologic signs and urinary problems, among other events. The FDA also updated the Librela label to reflect these reports [2][9].

The specific categories of concern include:

• Neurologic signs such as ataxia, tremors, and seizures
• Urinary problems such as difficulty urinating, incontinence, or urinary tract infections
• Musculoskeletal events, including lameness that worsens or new joint involvement

These reports do not prove that Librela caused the events in every case. Dogs with osteoarthritis are often older and may have concurrent neurologic or urinary disease. But the temporal association and the biologic plausibility of NGF blockade affecting nerve and urinary function are enough that the FDA judged the reports worth communicating to veterinarians and owners.

The RPOA question

The most serious safety question surrounding anti-NGF antibodies comes from human medicine. Tanezumab, an anti-NGF monoclonal antibody developed for human osteoarthritis, failed to achieve FDA marketing approval in 2021. The primary concern was a syndrome called rapidly progressive osteoarthritis (RPOA), in which joint destruction accelerates far faster than expected, sometimes leading to collapse of the joint and the need for replacement surgery [16].

RPOA has not been established as a bedinvetmab-associated condition in dogs. A letter to the editor addressing questions about joint findings in the canine safety studies concluded that the radiographic and histopathologic bone findings were incidental and not bedinvetmab-associated [16]. The same letter noted that bedinvetmab had been on the market for more than three years in some regions without a confirmed RPOA signal [16].

However, a separate group of veterinarians has published a safety concern arguing that NGF plays critical roles in bone and cartilage homeostasis, and that blocking it could mask early structural deterioration and potentially accelerate joint destruction in dogs as it did in humans [12]. That publication describes emerging clinical signals and calls for vigilant adverse event reporting [12]. A critical appraisal of the safety literature found conflicting evidence, with stronger evidence supporting safety in the controlled trial settings but a disproportionality analysis showing musculoskeletal adverse events reported more frequently with bedinvetmab than with traditional therapeutics [17].

This is an unresolved scientific debate. The honest position for an owner is that Librela has a reasonable safety profile in controlled trials, that serious adverse events appear to be rare based on post-approval reporting, and that a small number of veterinarians and researchers believe the true risk of joint-related harm may be underrecognized. Monitoring and reporting are the appropriate responses.

What to watch for at home

Owners should contact their veterinarian if a dog shows any of the following after a Librela injection:

• New or worsening wobbliness, tremors, or seizures
• Difficulty urinating, accidents in the house, or straining to urinate
• Sudden worsening of lameness, especially in a joint that was not previously affected
• Swelling, heat, or obvious pain in a joint
• Lethargy, loss of appetite, or vomiting that does not resolve
• Any reaction at the injection site

These signs may or may not be related to the drug. The veterinarian needs to know about them either way.

Who Should Not Receive Librela

The label specifies that Librela is for dogs 12 months of age and older. It should not be used in dogs with known hypersensitivity to bedinvetmab or the injection's inactive ingredients [9]. Safety has not been established in pregnant, breeding, or lactating dogs, so it is generally avoided in those groups.

Dogs with pre-existing neurologic disease require careful consideration. The FDA's Dear Veterinarian letter specifically highlighted neurologic adverse events [2]. A dog with a seizure history or a diagnosed neurologic condition may still be a candidate if the veterinarian judges the benefits to outweigh the risks, but that conversation should be explicit.

Dogs with urinary disease also warrant caution. The letter noted urinary problems among reported events [2]. A dog with a history of urinary obstruction, recurrent urinary tract infections, or incontinence should be evaluated before starting Librela and monitored afterward.

Drug Interactions

The best-studied interaction is with carprofen. A laboratory safety study evaluated short-term concurrent administration of bedinvetmab and carprofen in dogs and found no treatment-related adverse changes [7]. This supports the common clinical practice of combining Librela with an NSAID when a dog needs more pain control than either alone provides.

Beyond that, the interaction profile of bedinvetmab is not fully mapped. Because it is a monoclonal antibody, it is not metabolized by the liver enzymes that process most small-molecule drugs, so classic drug-drug interactions are less of a concern. But the immune system can develop anti-drug antibodies that affect how long the drug stays active, and concurrent immunosuppressive therapy could theoretically alter that response.

Owners should tell the veterinarian about every medication, supplement, and topical product the dog receives. This includes joint supplements, fish oil, CBD products, and anything obtained without a prescription.

How Librela Compares with NSAIDs

NSAIDs have been the first-line treatment for canine osteoarthritis for decades. Drugs like carprofen, meloxicam, deracoxib, and grapiprant reduce inflammation and pain by inhibiting cyclooxygenase enzymes. They are effective, widely available, and relatively inexpensive. They are also associated with gastrointestinal, kidney, and liver risks, especially with long-term use or in dogs with pre-existing disease.

Librela works differently. It does not inhibit cyclooxygenase. It does not reduce inflammation in the joint. It reduces the pain signal by neutralizing NGF. This gives it a different risk profile. The gastrointestinal and kidney risks that dominate NSAID safety discussions are not the primary concern with Librela. The concerns are neurologic, urinary, and the unresolved question of joint-related harm.

A randomized trial comparing bedinvetmab with meloxicam found similar efficacy on the primary measure, with a non-significant numerical advantage for bedinvetmab [13]. A critical appraisal of the safety literature found that in one comparison, bedinvetmab had fewer associated adverse events than meloxicam over a two-month period, though the difference was not statistically significant [17].

The practical comparison looks like this:

Many dogs do best on a combination. A dog that gets partial relief from an NSAID may get additional relief from Librela, and vice versa. The veterinarian can adjust the plan based on response and tolerance.

Solensia: The Cat Equivalent

Solensia is the feline equivalent of Librela. Its active ingredient is frunevetmab, a fully felinized anti-NGF monoclonal antibody [6][5]. It works by the same mechanism, binding NGF and preventing it from activating pain-sensing nerves. It is given as a monthly subcutaneous injection at 1 to 2.8 mg/kg [5].

The development path was similar. Early studies showed that a felinized anti-NGF antibody reduced signs of lameness in a kaolin-induced inflammatory pain model in cats [6]. A pilot proof-of-concept study in cats with degenerative joint disease-associated pain found that a single treatment significantly increased objectively measured activity and improved owner-completed pain and mobility scores [18].

Cats and dogs are different species with different drug handling, different dosing, and different safety profiles. Librela is not for cats and Solensia is not for dogs. Owners with both a dog and a cat on anti-NGF therapy should keep the products separate and follow the veterinarian's instructions for each.

Questions to Ask Your Veterinarian

Before starting Librela, consider asking:

1. What evidence do we have that my dog's pain is osteoarthritis-related?
2. Is my dog a candidate for Librela, or should we try something else first?
3. What is the plan if the first two or three injections do not help?
4. Should my dog stay on an NSAID, or should we change the NSAID dose?
5. What specific signs should I watch for at home, and when should I call you?
6. How will we monitor for neurologic or urinary problems?
7. Is there any reason my dog should not receive this drug?
8. What is the plan if we see a possible adverse event?
9. How does the cost of Librela compare with our current treatment?
10. Are there other therapies we should combine with Librela?

Limitations and When to Contact a Veterinarian

This article provides general information about Librela and osteoarthritis pain in dogs. It cannot account for your dog's specific medical history, concurrent diseases, or current medications. Every decision about starting, continuing, or stopping Librela should be made with a licensed veterinarian who has examined your dog.

Contact a veterinarian promptly if your dog shows any of the following after a Librela injection:

• New or worsening neurologic signs, including wobbliness, tremors, or seizures
• Difficulty urinating, straining to urinate, or loss of house training
• Sudden severe lameness, especially in a joint that was not previously affected
• Swelling, heat, or signs of severe pain in any joint
• Vomiting, diarrhea, or loss of appetite that lasts more than 24 hours
• Lethargy or weakness that is new or worsening
• Any signs of an allergic reaction, including facial swelling, hives, or difficulty breathing

If your dog's pain is not adequately controlled after two or three monthly injections, tell your veterinarian. Lack of efficacy is the most commonly reported issue in post-approval surveillance [1], and it may mean the dog needs a different or additional approach.

Frequently Asked Questions

What is Librela for dogs?

Librela is a prescription injectable medication for dogs with osteoarthritis pain. Its active ingredient is bedinvetmab, a monoclonal antibody that binds and neutralizes nerve growth factor. It is given as a subcutaneous injection once a month by a veterinarian.

How long does Librela take to work in dogs?

Some owners notice improvement within 7 to 14 days after the first injection. Clinical trial data show significant improvement from day 7, and quality of life studies show measurable benefit by day 14. The full effect may not be apparent until after the second or third monthly dose.

What are the most common Librela side effects in dogs?

In controlled trials, adverse events were similar between Librela and placebo. Post-approval surveillance has identified rare reports of increased thirst, wobbliness, increased urination, loss of appetite, lethargy, and death. The FDA issued a Dear Veterinarian letter in December 2024 about neurologic and urinary adverse events and updated the label.

Is Librela safer than NSAIDs for dogs?

Librela and NSAIDs have different risk profiles. NSAIDs carry gastrointestinal, kidney, and liver risks. Librela carries neurologic, urinary, and unresolved joint-related concerns. A randomized trial found similar efficacy between Librela and meloxicam. The choice depends on the individual dog's health status and tolerance.

Can Librela be given with other arthritis medications?

Yes, Librela can be combined with other treatments under veterinary supervision. A laboratory safety study found no treatment-related adverse changes when bedinvetmab was given with carprofen, an NSAID. Many dogs receive Librela alongside an NSAID, joint supplements, or physical therapy.

How much does Librela cost for dogs?

Cost varies by clinic, region, and dog size. This article does not provide specific pricing because it depends on factors that change over time and by location. Owners should ask their veterinarian for an estimate.

Is Librela the same as Solensia?

No. Librela is for dogs and contains bedinvetmab. Solensia is for cats and contains frunevetmab. They work by the same mechanism, neutralizing nerve growth factor, but they are different drugs for different species and are not interchangeable.

What should I do if my dog has a bad reaction to Librela?

Contact your veterinarian immediately if your dog shows neurologic signs, urinary problems, sudden severe lameness, or any other concerning change after a Librela injection. Your veterinarian can assess the dog, provide supportive care, and report the event to the manufacturer and the FDA.

Related Articles

• What Are the Side Effects of Steroid Injections for Dogs?
• How to Give Your Dog a Shot at Home: Insulin and Other Injections
• What Are the Side Effects of Clavamox for Dogs?
• What Are the Side Effects of Gabapentin for Dogs?
• What Are the Side Effects of Vetmedin for Dogs?
• What Are the Side Effects of Prednisone in Dogs?
• Limber Tail in Dogs (Swimmer's Tail): Causes and Recovery

Sources

1. Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™).
2. Dear Veterinarian Letter notifying ... (fda.gov)
3. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody.
4. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis.
5. Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study.
6. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.
7. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
8. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats.
9. Librela™ (dailymed.nlm.nih.gov)
10. Beyond Osteoarthritis: Emerging Applications of Anti-NGF Monoclonal Antibodies in Pain Management in Dogs and Cats.
11. A fully caninised anti-NGF monoclonal antibody for pain relief in dogs.
12. Bedinvetmab (Librela/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting.
13. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis.
14. Efficacy of bedinvetmab on pain, activity, and body composition in obese dogs with osteoarthritis: A randomized double-blind placebo-controlled trial.
15. Bedinvetmab, alone or in combination with photobiomodulation and pulsed electromagnetic field therapy, on pain and quality of life in dogs with hip osteoarthritis.
16. Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
17. A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody.
18. A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study.